| Primary |
| Lymphoma |
52.6% |
| Stem Cell Transplant |
31.6% |
| Acute Myeloid Leukaemia |
15.8% |
|
| Treatment Related Secondary Malignancy |
66.7% |
| Encephalopathy |
16.7% |
| Pharmaceutical Product Complaint |
16.7% |
|
| Secondary |
| Burkitt's Lymphoma |
23.4% |
| Lymphoma |
22.2% |
| Product Used For Unknown Indication |
12.3% |
| Prophylaxis |
7.9% |
| Non-hodgkin's Lymphoma |
4.8% |
| Acute Myeloid Leukaemia |
3.9% |
| Ill-defined Disorder |
2.9% |
| Drug Use For Unknown Indication |
2.6% |
| Immunosuppression |
2.6% |
| Lymphocytic Leukaemia |
2.5% |
| Neuroblastoma |
2.1% |
| Bone Sarcoma |
2.0% |
| Diffuse Large B-cell Lymphoma |
1.7% |
| Stem Cell Transplant |
1.5% |
| Bone Marrow Conditioning Regimen |
1.4% |
| Acute Lymphocytic Leukaemia |
1.3% |
| Cord Blood Transplant Therapy |
1.3% |
| Sarcoma |
1.3% |
| Osteosarcoma |
1.2% |
| Multiple Myeloma |
1.1% |
|
| Pneumonitis |
44.1% |
| Renal Impairment |
15.3% |
| Toxicity To Various Agents |
3.6% |
| Tumour Lysis Syndrome |
3.6% |
| Weight Decreased |
3.6% |
| Pulmonary Toxicity |
2.7% |
| Skin Exfoliation |
2.7% |
| Superinfection |
2.7% |
| Venoocclusive Liver Disease |
2.7% |
| Engraft Failure |
1.8% |
| Leukaemia Cutis |
1.8% |
| Pyrexia |
1.8% |
| Renal Tubular Disorder |
1.8% |
| Serum Ferritin Increased |
1.8% |
| Sinusitis |
1.8% |
| Splenic Neoplasm Malignancy Unspecified |
1.8% |
| Staphylococcal Infection |
1.8% |
| Vomiting |
1.8% |
| Wound Dehiscence |
1.8% |
| Acute Myeloid Leukaemia |
0.9% |
|
| Concomitant |
| Product Used For Unknown Indication |
22.8% |
| Acute Myeloid Leukaemia |
10.1% |
| Drug Use For Unknown Indication |
7.3% |
| Acute Lymphocytic Leukaemia |
6.2% |
| Stem Cell Transplant |
6.2% |
| Bone Sarcoma |
5.9% |
| Cord Blood Transplant Therapy |
5.4% |
| Prophylaxis Against Graft Versus Host Disease |
5.4% |
| Non-hodgkin's Lymphoma |
5.1% |
| Chemotherapy |
4.2% |
| Immunosuppression |
3.4% |
| Prophylaxis |
3.4% |
| Acute Lymphocytic Leukaemia Recurrent |
2.5% |
| Bone Marrow Conditioning Regimen |
2.0% |
| Ewing's Sarcoma |
2.0% |
| Mantle Cell Lymphoma |
1.7% |
| Nuclear Magnetic Resonance Imaging |
1.7% |
| Premedication |
1.7% |
| Vomiting |
1.7% |
| Acute Myeloblastic Leukemia |
1.4% |
|
| Febrile Bone Marrow Aplasia |
8.0% |
| Vena Cava Filter Insertion |
8.0% |
| Death |
6.0% |
| Drug Ineffective |
6.0% |
| Rash |
6.0% |
| Thrombotic Microangiopathy |
6.0% |
| Venoocclusive Liver Disease |
6.0% |
| Vomiting |
6.0% |
| Haematuria |
4.0% |
| Influenza |
4.0% |
| Neoplasm Malignant |
4.0% |
| Osteonecrosis |
4.0% |
| Pancreatic Disorder |
4.0% |
| Renal Failure |
4.0% |
| Respiratory Failure |
4.0% |
| Tenderness |
4.0% |
| Tooth Extraction |
4.0% |
| Toxic Encephalopathy |
4.0% |
| Type Iv Hypersensitivity Reaction |
4.0% |
| Weight Decreased |
4.0% |
|
